Q1 2024 13F Holders as of 3/31/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
59.9M
-
Number of holders
-
28
-
Total 13F shares, excl. options
-
9.6M
-
Shares change
-
+442K
-
Total reported value, excl. options
-
$19.8M
-
Value change
-
+$915K
-
Put/Call ratio
-
2.8
-
Number of buys
-
11
-
Number of sells
-
-10
-
Price
-
$2.06
Significant Holders of Eledon Pharmaceuticals, Inc. - Common Stock (ELDN) as of Q1 2024
33 filings reported holding ELDN - Eledon Pharmaceuticals, Inc. - Common Stock as of Q1 2024.
Eledon Pharmaceuticals, Inc. - Common Stock (ELDN) has 28 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 9.6M shares
of 59.9M outstanding shares and own 16.02% of the company stock.
Largest 10 shareholders include BVF INC/IL (4.33M shares), ARMISTICE CAPITAL, LLC (2.3M shares), VANGUARD GROUP INC (969K shares), Woodline Partners LP (652K shares), Ensign Peak Advisors, Inc (443K shares), GEODE CAPITAL MANAGEMENT, LLC (181K shares), CM Management, LLC (160K shares), SUSQUEHANNA INTERNATIONAL GROUP, LLP (99.8K shares), RENAISSANCE TECHNOLOGIES LLC (87.1K shares), and JMAC ENTERPRISES LLC (58K shares).
This table shows the top 28 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.